1

1

1

Breakthrough innovation in the fight against pancreatic cancer

Breakthrough innovation in the fight against pancreatic cancer

CC&C is a Medtech start-up. We rely on the latest discoveries in the field of oncology and in particular physical oncology and mechanobiology, to develop a treatment against pancreatic cancer.

Learn more about our technology…

In 2016, we published our Proof of Concept in PlosOne. This experiment validated the action of mechanical stress on a grafted tumor in mice. This is the first time in the world that such a result is obtained on live animals, and not in cell cultures.

Read our article …

Today, our goal is to experimentally validate the action of our device on human pancreatic cancer grafted in mouse pancreas. To do this, we have initiated two partnerships, one in the United States with the prestigious Stanford University, the other in a European consortium around the Bichat Faculty of Medicine in Paris, a world leader in Digestive Oncology.

Learn more about our Proof of Efficacy…

Our medium-term strategy: to finish research within two years and move on to a human prototype, with the goal of a first human experiment in 2022.

Why such a rapid development?

What is Cell Constraint & Cancer ?

of research

raised in 2018

before placing on the market

subscribe to our capital increase

Invest in a breakthrough innovation, unique and patented.

Development faster than a drug.

Latest news from CC&C

Results for the 3rd quarter 2018

- RESULTS OF THE CALL FOR EUROPEAN PROJECTS FET-OPEN - A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIERWe have received the answer from the European Commission: unfortunately, it is negative. However, we get a very good grade, and the comments of the...
Lire la suite

Proof of efficacy for dummies

This article is for curious but unscientific readers. Expert readers will find a description of the planned protocol within the NanoStress consortium here. For 2 years, we have announced everywhere that to obtain our Proof of Efficacy will mark the...
Lire la suite

A joint experiment between CC&C and the IBDM

- Mechanical Signals and Cancer: a new experiment on colon cancer. First results expected early 2019. Based in Marseille, the IBDM brings together about twenty research teams that explore the field of developmental biology and associated pathologies, with daily...
Lire la suite

1 + 2 =

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles